Finally, we wanted to explore the expression landscape of DLL3 in non-neuroendocrine carcinomas, in which DLL3 expression was exceedingly rare (and if found, mostly weak), which argues that expression of DLL3 is largely restricted to NEN. This evidence concerns the gene DLL3 and neuroendocrine carcinoma.